Tirzepatide
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Tirzepatide: From Type 2 Diabetes and Weight Management to Osteoarthritis
One-Sentence Summary
Tirzepatide is a once-weekly injectable dual GIP/GLP-1 receptor agonist, marketed as Mounjaro and Zepbound for glycaemic control in type 2 diabetes and for weight management. The TxGNN model predicts it may be effective for osteoarthritis (the strongest-supported of its top 10 predictions), with 1 clinical trial and 19 publications currently supporting this direction. The only trial is a Phase 4 study that is still recruiting, so direct efficacy evidence is not yet available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes (glycaemic control) and weight management in obesity, per pharmacology data compiled for this report; license-level indication text is not available |
| Predicted New Indication | Osteoarthritis (knee osteoarthritis in patients with obesity is the trial focus) |
| TxGNN Prediction Score | 95.92% |
| Evidence Level | L2 |
| US Market Status | Cancelled only (2 NDAs listed as cancelled) |
| Number of NDAs | 2 |
| Recommended Decision | Proceed with Guardrails |
Note: The top-ranked prediction by TxGNN score is gout (96.75%), but it has no registered trials and only L3 evidence. Osteoarthritis was chosen as the lead indication because it has a dedicated clinical trial and the most supporting literature.
Why is This Prediction Reasonable?
Detailed mechanism-of-action text is not available in the data compiled for this report. Pharmacology data show that tirzepatide acts on two targets, the GIP receptor (GIPR) and the GLP-1 receptor (GLP1R). Its efficacy in type 2 diabetes and obesity is established: in the SURMOUNT-1 trial, patients achieved roughly 15-20% body-weight reduction depending on dose.
Obesity is a key modifiable risk factor for knee osteoarthritis, acting through mechanical joint loading and systemic inflammation. Substantial weight loss with tirzepatide could therefore reduce pain and improve function. Reviews also propose a weight-independent “incretin-joint axis”, in which incretin-based therapies may influence synovial inflammation and cartilage catabolism, though this remains a hypothesis.
Caveat: most of the supporting literature consists of reviews and cost or modelling analyses, not primary efficacy trials in osteoarthritis.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06191848 | Phase 4 | Recruiting | 352 | STOP KNEE-OA: randomised, double-blind, placebo-controlled trial of weekly subcutaneous tirzepatide for 72 weeks in people with obesity and knee osteoarthritis. The main aim is to see whether tirzepatide reduces the number of participants who need a knee replacement. Started November 2024; no results yet. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41039116 | 2025 | Systematic review / Meta-analysis | Nature Medicine | Network meta-analysis of obesity medications versus placebo or active comparators, assessing weight loss and obesity-related complications |
| 40953447 | 2025 | Cost-effectiveness analysis | Annals of Internal Medicine | Cost-effectiveness of semaglutide and tirzepatide in knee osteoarthritis with obesity; notes that GLP-1 RAs lead to substantial weight loss and pain reduction |
| 39129529 | 2024 | Not classified | Expert Opinion on Pharmacotherapy | Impact of approved anti-obesity medications on osteoarthritis; the effect on osteoarthritis risk remains uncertain |
| 42546112 | 2026 | Not classified | Knee Surg Sports Traumatol Arthrosc | GLP-1 RAs in hip, knee and shoulder arthroplasty; may influence inflammation, osteoarthritic symptoms and perioperative complications |
| 41547366 | 2026 | Review | Lancet | Metabolic, cardiovascular and renal benefits of GLP-1 receptor agonists and next-generation incretin medications |
| 42208956 | 2026 | Review | Lancet Diabetes & Endocrinology | Multisystem benefits of obesity medications, based on RCTs and meta-analyses |
| 41410846 | 2025 | Narrative review | Current Atherosclerosis Reports | Semaglutide and tirzepatide in obesity and weight-related comorbidities; tirzepatide produced 17.4-20.8% greater weight loss than placebo |
| 41748946 | 2026 | Pharmacovigilance study | Naunyn-Schmiedeberg’s Arch Pharmacol | FAERS analysis of musculoskeletal adverse events with incretin-based drugs including tirzepatide |
| 38015216 | 2023 | Review | JAMA | Obesity management in adults; obesity is linked to higher rates of osteoarthritis, among other conditions |
| 40100584 | 2025 | Narrative review | Current Psychiatry Reports | Sex differences in obesity treatment, including studies in knee osteoarthritis |
Other predictions with some literature support:
- Gout (score 96.75%, L3): a post hoc analysis of the SURMOUNT-1 RCT (PMID 41198460, Annals of the Rheumatic Diseases, 2026) examined whether tirzepatide lowers serum uric acid through weight reduction. A narrative review (PMID 42469142) discusses weight management in gout. No gout-specific trials are registered.
- Rheumatoid arthritis (score 93.60%, L4): evidence is indirect, mainly an observational study of GLP-1 RAs in RA patients (PMID 40932015) and reviews. There are no registered trials.
- Other predictions (pseudoachondroplasia, osteoarthritis susceptibility, benign prostatic hyperplasia, Hunter-Thompson acromesomelic dysplasia, brachyolmia, brachyolmia-amelogenesis imperfecta syndrome, myosclerosis) have no trials or literature and are model predictions only (L5). The rare skeletal dysplasias have no plausible mechanistic link to incretin signalling.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA215866 | Mounjaro (Eli Lilly and Company) | Injection, solution | Indication text not available; status: cancelled |
| NDA217806 | Zepbound (Eli Lilly and Company) | Injection, solution | Indication text not available; status: cancelled |
Both authorizations are listed as cancelled in the regulatory data compiled for this report, and no valid authorization is recorded. This conflicts with the pharmacology information, which describes FDA approval for type 2 diabetes (May 2022) and weight management (November 2023). The status should be verified against current FDA records.
Safety Considerations
- Drug Interactions: The interaction query completed, but it returned only pharmacological target information (GIP receptor and GLP-1 receptor), not drug-drug interactions. No clinically relevant interacting drugs are listed.
- Musculoskeletal adverse events: A FAERS pharmacovigilance study (PMID 41748946) examined musculoskeletal adverse events with incretin-based drugs, including tirzepatide. This is relevant to a musculoskeletal indication and should be reviewed.
Please refer to the package insert for key warnings and contraindications, which are not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Osteoarthritis has a plausible mechanism (weight loss reducing joint load and inflammation), a high TxGNN score, and a dedicated randomised, placebo-controlled Phase 4 trial. However, that trial is still recruiting (expected completion 2037) and has no results, and most of the literature consists of reviews and modelling. Gout is a reasonable secondary research question. The remaining predictions should be on Hold.
To proceed, the following is needed:
- Results from NCT06191848 (STOP KNEE-OA), or other primary efficacy data in osteoarthritis
- FDA package insert warnings and contraindications, which are currently missing and block safety screening
- Mechanism-of-action data from DrugBank
- Verification of the current US market and authorization status (the data show both NDAs as cancelled)
- For gout, a dedicated outcome trial (flares, uric acid) beyond the SURMOUNT-1 post hoc analysis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.